Ignite Creation Date:
2025-12-25 @ 4:36 AM
Ignite Modification Date:
2025-12-26 @ 3:38 AM
Study NCT ID:
NCT05909618
Status:
RECRUITING
Last Update Posted:
2025-07-22
First Post:
2023-05-01
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases
Sponsor:
Sheba Medical Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-07-11
Start Date Type:
ACTUAL
Primary Completion Date:
2028-07-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-07-30
Completion Date Type:
ESTIMATED
First Submit Date:
2023-05-01
First Submit QC Date:
None
Study First Post Date:
2023-06-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-17
Last Update Post Date:
2025-07-22
Last Update Post Date Type:
ACTUAL